CVS Health (CVS) is back in the spotlight after reporting quarterly earnings that surpassed expectations and lifting its full year profit outlook, with renewed investor attention also linked to commentary from Jim Cramer.

Despite a small pullback in the latest session, with the 1 day share price return declining 2.52% to close at US$102.08, CVS Health has seen momentum build over recent months. The 30 day share price return is 6.41% and the 90 day share price return is 30.50%. Total shareholder return over the past year sits at 58.69%, pointing to investors reassessing both growth prospects and risk after stronger earnings, raised guidance, court approval to sell Omnicare and fresh attention on the stock.

If earnings driven moves at CVS Health have you looking for other ideas in the sector, this could be a good time to scan for opportunities in 40 healthcare AI stocks

CVS Health now trades only slightly below the average analyst price target, yet it sits at a steep discount to some intrinsic value estimates. Is the recent rally already pricing in the recovery, or is there still a valuation gap?

Most Popular Narrative: 190% Undervalued

According to the most followed valuation narrative, CVS Health has a fair value estimate of about $104, which sits only slightly above the recent $102.08 close and frames the current rally as modest relative to that implied upside.

By both absolute and relative bases, CVS is undervalued and, therefore, an attractive investment, most especially for value investors who would be more patient and wait for the company to solve its temporary problems. The discount of the stock versus its sector peers and estimate of intrinsic value point toward a strong upside potential, assuming that CVS delivers on its cost-cutting initiatives and effectively integrates recent healthcare acquisitions. It could also give CVS an opportunity, if successful, for re-rating toward a valuation more aligned with the average within its industry segments, thereby creating shareholder value.

The current fair value call on CVS Health rests on a detailed cash flow build, specific revenue growth expectations, and an earnings path that leans heavily on margin repair. Curious which parts of the business carry most of the weight in that model, and how long the narrative expects the turnaround to take?

Result: Fair Value of $104.01 (UNDERVALUED)

However, CVS Health still faces risks, including pressure from higher medical costs in its Health Care Benefits segment and execution uncertainty around its $2b restructuring plan.

Another View: CVS Health Looks Expensive on Earnings

While the SWS DCF model points to CVS Health as deeply undervalued, the P/E picture tells a different story. CVS trades at about 44.4x earnings versus 25.9x for the US Healthcare industry and a 20x peer average, which is above a fair ratio estimate of 40.6x. That gap suggests investors may already be paying up on this metric, raising the question of how much safety margin is really left if sentiment shifts.

Next Steps

With CVS Health facing a mix of risks and rewards, this is the moment to act quickly, review the underlying data, and shape your own view using the 2 key rewards and 5 important warning signs

Looking for more investment ideas beyond CVS Health?

Do not stop with CVS Health. Use powerful screeners to quickly surface fresh stock ideas that match your style before the next wave of opportunities moves without you.

• Target reliable cash generators using the solid balance sheet and fundamentals stocks screener (47 results) to focus on companies with stronger foundations and cleaner financial profiles.
• Hunt for potential bargains by scanning the 41 high quality undervalued stocks and see which stocks currently trade below their assessed worth.
• Prioritize resilience by checking the 74 resilient stocks with low risk scores so you can focus on companies with steadier risk scores when building your watchlist.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.